Assessment of fibrotic burden among chronic hepatitis B virus-infected patients with normal transaminase level

Corresponding author : Seung Up Kim Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea Tel: +82-2-2228-1994; Fax: +82-2-393-6884 E-mail: ksukorea@yuhs.ac https://orcid.org/0000-0002-9658-8050 Abbreviations: ALT, alanine aminotransferase; AVT, antiviral therapy; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; IT, immune tolerant; TE, transient elastography

[1]  Hongbing Shen,et al.  Hepatitis B virus infection and risk of non‐alcoholic fatty liver disease: A population‐based cohort study , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[2]  Casado Marta,et al.  Characterization and evaluation of liver fibrosis grade in patients with chronic hepatitis B virus infection and normal transaminases , 2018, Clinical and molecular hepatology.

[3]  B. McMahon,et al.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance , 2018, Hepatology.

[4]  H. Lee,et al.  High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B , 2017, Gut.

[5]  Vincent Wai-Sun Wong,et al.  New trends on obesity and NAFLD in Asia. , 2017, Journal of hepatology.

[6]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[7]  Marcello Maida,et al.  The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease , 2015, Hepatology.

[8]  V. Wong,et al.  Hepatitis B virus infection and fatty liver in the general population. , 2012, Journal of hepatology.

[9]  Y. N. Park,et al.  Risk assessment of hepatitis B virus–related hepatocellular carcinoma development using liver stiffness measurement (FibroScan) , 2011, Hepatology.

[10]  최은희,et al.  Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). , 2011 .

[11]  V. Wong,et al.  Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B , 2008, Gut.

[12]  Eva Herrmann,et al.  Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. , 2008, Gastroenterology.

[13]  Patrice Cacoub,et al.  Meta-analyses of FibroTest diagnostic value in chronic liver disease , 2007, BMC gastroenterology.

[14]  P. Loehrer,et al.  Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level , 2007 .

[15]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[16]  R. Fisher,et al.  Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values , 2003, Hepatology.

[17]  M. Brunetto,et al.  Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. , 2002, Journal of hepatology.